Targeted Treatment Options for Patients With AML and FLT3 or IDH1/2 Mutations

In this podcast episode, Sarah M. Tinsley, PhD, APRN, AOCN, discusses targeted therapy with FLT3 and IDH1/2 inhibitors in AML, with a focus on the nursing perspective. Topics include:Approved and emerging treatment options for FLT3-mutated AMLManagement of adverse events associated with FLT3 inhibitorsTherapies for IDH1- and IDH2-mutated AMLIdentifying and managing differentiation syndrome associated with IDH1/2 inhibitorsPresenters:Sarah M. Tinsley, PhD, APRN, AOCNNurse PractitionerCourtesy Assistant ProfessorDepartment of Malignant HematologyMoffitt Cancer CenterUniversity of South FloridaTampa, Florida  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.